AGOMAB THERAPEUTICS
AgomAb is developing molecular therapies for the regeneration of damaged tissues. Their unique agonistic monoclonal antibody molecules (“agomAbs”) stimulate molecular and cellular repair mechanisms that have the potential to restore organ function in patients with fibrotic, inflammatory, autoimmune and degenerative diseases.
AGOMAB THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Ghent, Oost-Vlaanderen, Belgium
Country:
Belgium
Website Url:
http://www.agomab.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
236.96 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Tag Manager Apple Mobile Web Clips Icon Google Font API Google Analytics Google Maps WordPress
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Cellestia
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression.
Pliant Therapeutics
Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-10-28 | Origo Biopharma | Origo Biopharma acquired by AgomAb Therapeutics | N/A |
Investors List
Andera Partners
Andera Partners investment in Series C - AgomAb Therapeutics
Redmile Group
Redmile Group investment in Series C - AgomAb Therapeutics
Pfizer
Pfizer investment in Series C - AgomAb Therapeutics
Asabys Partners
Asabys Partners investment in Series C - AgomAb Therapeutics
Fidelity
Fidelity investment in Series C - AgomAb Therapeutics
Dawn Biopharma
Dawn Biopharma investment in Series C - AgomAb Therapeutics
Canaan Partners
Canaan Partners investment in Series C - AgomAb Therapeutics
Pontifax
Pontifax investment in Series C - AgomAb Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series C - AgomAb Therapeutics
EQT Life Sciences
EQT Life Sciences investment in Series C - AgomAb Therapeutics
Key Employee Changes
Official Site Inspections
http://www.agomab.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.36 K
- Host name: 20.50.64.17
- IP address: 20.50.64.17
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AgomAb Therapeutics"
About Us – Agomab Therapeutics
The Agomab team has built a strong scientific foundation in targeting growth factors and modulating related molecular pathways through novel monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate …See details»
Agomab Therapeutics – Restoring Organ Function
Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral …See details»
Agomab - LinkedIn
Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function.See details»
AgomAb Therapeutics - Crunchbase Company Profile …
Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.See details»
Executive Committee – Agomab Therapeutics
Philippe joined Agomab as CMO in 2021. He was previously the CMO at Genkyotex where he led the company’s clinical development activities for the treatment of several fibrotic …See details»
AgomAb Therapeutics | Boehringer Ingelheim Venture Fund
Agomab is focused on achieving disease modification by modulating inflammation and fibrosis in chronic indications such as Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary …See details»
Agomab Therapeutics - EQT Group
Agomab Therapeutics is a biotechnology company developing therapies that aim to preserve and restore organ function in fibrotic diseases.See details»
Agomab Therapeutics NV - Ghent, Belgium - bionity.com
Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. By …See details»
AgomAb Company Profile - Office Locations, Competitors, …
AgomAb has 1 employees at their 1 location and $97.61 m in total funding,. See insights on AgomAb including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Agomab Therapeutics – Restoring Organ Function
Agomab Therapeutics NV (‘Agomab’) today announced that it has appointed David Epstein as non-executive board member and Chairman of its Board of Directors. David is an industry veteran and most recently served as Seagen’s …See details»
Agomab Therapeutics Completes Acquisition of Origo …
Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28 th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ …See details»
Agomab Therapeutics to Acquire Origo Biopharma
A highly competent and committed organization. Agomab has built an impressive and driven R&D and corpor te team with access to high-quality resources. We are truly excited to take this step …See details»
Agomab Therapeutics to Acquire Origo Biopharma
Agomab will integrate these programs into its growing pipeline and add the entire Origo team and facilities to its current organization. As such, Agomab’s corporate footprint will comprise its …See details»
AgomAb Therapeutics - Funding, Financials, Valuation & Investors
Agomab is a biotechnology company developing therapies that maintains and restores organ function in diseases characterized by fibrosis.See details»
AgomAB Therapeutics - VentureRadar
"AgomAb is pioneering therapies that modulate regenerative pathways to achieve structural tissue repair and functional organ recovery. Our growing pipeline of highly specific monoclonal …See details»
Agomab - Asabys Partners
Agomab’s pipeline consists of its lead candidate AGMB-129, a gastrointestinal tract restricted ALK-5 inhibitor for the treatment of fibrostenotic Crohn’s disease. The second TGF-ß-targeting …See details»
Agomab raises $100m for Crohn’s drug, and other financings
4 days ago Agomab Therapeutics has closed a $100 million third-round financing, heading a list of recent funding rounds that also features AstronauTx, MinervaX, Precede Bio and …See details»
Pipeline – Agomab Therapeutics
Agomab aims to resolve these processes through a broad pipeline of small molecule and antibody drug candidates designed for their unique and novel modes of actions against well-validated …See details»
Agomab Therapeutics to Acquire Origo Biopharma - ASEBIO
Jan 19, 2022 Agomab Therapeutics NV (‘Agomab’) announced today that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage …See details»
FDA Approves Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) …
Apr 30, 2025 First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. New York, April 30, 2025 – …See details»